Business
IMMUPHARMA ATTENDING BIO-EUROPE
ImmuPharma PLC announced that its CEO, Tim McCarthy, COO, Dr. Tim Franklin, and CSO, Dr. Sebastien Goudreau, will attend the Bio-Europe Conference in Vienna from November 3-5, 2025. The Bio-Europe conference is the 31st annual biopharma partnering event, expecting over 5,700 life science professionals representing more than 3,000 companies across 60+ countries. The event is anticipated to facilitate more than 30,000 one-to-one meetings. Disclaimer*
About this update from Immupharma Plc
RNS REACH : 27 NOVEMBER 2025 ImmuPharma PLC ("ImmuPharma" or the "Company") IMMUPHARMA ATTENDING BIO-EUROPE 3-5 November 2025, Vienna ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025. BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science professionals from more than 3,000 companies across 60+ countries, facilitating more than 30,000 one-to-one meetings. This event makes it the leading life science partnering forum in Europe, fostering innovation, collaboration and growth in the biotech sector. For further information please contact: ImmuPharma PLC ( www.immupharma.co.uk ) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. For additional information about ImmuPharma please visit www.immupharma.co.uk . ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895. About Reach announcements Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.